Adding Pembrolizumab to Docetaxel Does Not Significantly Improve Outcomes in Patients with Previously Treated mCRPC By Ogkologos - April 9, 2025 725 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KEYNOTE-921 study Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR Longtime NPR Reporter Shares Diagnosis to Bring More Awareness to Metastatic... June 26, 2021 What Happens If More People Get Screened for Cancer? January 26, 2024 Metastatic Colorectal Cancer May Spread Early in the Disease, Study Finds July 22, 2019 A “Living Medicine:” Engineered E. coli Shrink Tumors in Mice December 11, 2024 Load more HOT NEWS 3 Things to Reduce Stress During Cancer Treatment: A Patient’s Perspective School Teacher’s Breast Cancer Journey Inspired Her to Move to Australia... Food for thought: new insights into how chemotherapy causes cachexia Some People with Rectal Cancer Can Skip Radiation Before Surgery
